Business
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the safety,
About this update from Werewolf Therapeutics, Inc.
[{"type":"text","content":"WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy Phase 1 Study of WTX-330 is intended to evaluate the safety, tolerability, and clinical activity of WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma Second clinical stage program of a new class of systemically delivered, conditionally activated INDUKINE™ therapeutics developed by Werewolf WATERTOWN, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating WTX-330, the Company’s lead INDUKINETM molecule targeting Interleukin-12 (IL-12). The Phase 1 clinical trial is a first-in-human, multi-center, open-label trial that will evaluate WTX-330 in patients with advanced or metastatic solid tumors or lymphoma resistant to checkpoint inhibitors or for which checkpoint inhibitors are not approved. “Dosing the first patient in our Phase 1 trial of WTX-330 marks the second INDUKINE molecule arising from our PREDATORTM protein engineering platform to enter the clinic. Our continued transition into a clinical stage company comes at an exciting time for Werewolf following the initiation of a Phase 1/1b clinical study of WTX-124 last year,” said Daniel J. Hicklin, Ph.D., Werewolf’s Founder and Chief Executive Officer. “WTX-330 serves as another example of our team's capacity to expand our clinical pipeline and validates our novel approach of developing conditionally activated cytokines as cancer therapies to improve outcomes for patients with hard-to-treat tumors.” “We are pleased to begin patient dosing in our Phase 1 clinical trial with WTX-330, a novel tumor-selective IL-12 therapy with the potential to address the shortcomings associated with recombinant IL-12, including toxicities resulting from off-tumor effects,” said Randi Isaacs, M.D., Chief Medical Officer of Werewolf Therapeutics. “WTX-330 has the potential to be the only systemic, conditionally active IL-12 therapy with normal tissue IL-12R receptor blockade to deliver the full potency of IL-12 directly to the tumor microenvironment...